Marshall Wace, LLP Regenxbio Inc. Transaction History

Marshall Wace, LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$16.46 - $19.99 $547,278 - $664,647	33,249 New	33,249 $547,000
Q1 2021 May 17, 2021	SELL	$33.61 - $49.95 $299,229 - $444,704	-8,903 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$26.52 - $49.35 $236,107 - $439,363	8,903 New	8,903 $404,000
Q3 2020 Nov 16, 2020	SELL	$27.01 - $40.26 $1.58 Million - $2.35 Million	-58,445 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$27.75 - $43.44 $1.54 Million - $2.41 Million	55,514 Added 1894.03%	58,445 $2.15 Million

Q1 2020 May 15, 2020	BUY	$21.5 - $54.2 $63,016 - $158,860	2,931 New	2,931 $95,000
Q1 2019 May 14, 2019	SELL	$40.82 - $62.45 $1.58 Million - $2.42 Million	-38,821 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$39.11 - $75.15 $12.4 Million - $23.9 Million	-317,965 Reduced 89.12%	38,821 $1.63 Million
Q3 2018 Nov 14, 2018	BUY	$65.0 - $82.15 $9.86 Million - $12.5 Million	151,737 Added 74.0%	356,786 $26.9 Million
Q2 2018 Aug 14, 2018	BUY	$27.2 - $74.35 $5.58 Million - $15.2 Million	205,049 New	205,049 $14.7 Million

193

42.1M

80.6K

55.2K

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $458M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.